
Lunit And Microsoft Collaborate To Advance AI-Driven Cancer Diagnosis
This marks a significant milestone in Lunit's mission to expand access to AI tools, particularly in the U.S. market, by leveraging Microsoft Azure's global cloud infrastructure and deep expertise in healthcare-focused AI technologies.
Key highlights of the collaboration include:
- Co-Development of AI Model Customization Service on Azure: Lunit and Microsoft collaborate to develop a service that allows fine-tuning of AI models using site-specific clinical data from each customer. This approach helps mitigate cross-site model performance variability-one of the key challenges in deploying AI in real-world clinical environments-and ensures more reliable, tailored outcomes in diverse clinical settings.
- Leveraging Microsoft's AI Platform for Innovative Workflow Solutions: Moving beyond point solutions, Lunit will leverage Microsoft's agentic AI frameworks-designed to support intelligent task automation-to develop end-to-end workflow automation tools. These solutions aim to simplify clinical decision-making and enhance operational efficiency across the care continuum.
"For AI to truly make an impact in healthcare, it must be accessible, scalable, and seamlessly integrated into clinical practice," said Brandon Suh, CEO of Lunit. "Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the U.S. and beyond. This collaboration brings us one step closer to delivering high-quality, consistent care through AI-at scale."
"With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations," said Naveen Valluri, General Manager, Health and Life Sciences Data and AI at Microsoft. "By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of intelligent, integrated solutions for radiology and beyond."
###
About Lunit
Founded in 2013, Lunit (KRX:328130) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 6,500 medical institutions in more than 65 countries. Lunit clinical studies have been featured in top-tier journals-including The Lancet Digital Health and Journal of Clinical Oncology-and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit .
SOURCE Lunit

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Multibank Group Confirms $MBG Token TGE Set For July 22, 2025
- Status Unveils First Gasless L2 On Linea With 100% Community Yield Allocation Mechanism
- Polemos Launches $PLMS Token On MEXC And Uniswap, Advancing Web3 Gaming Infrastructure
- Everstake Brings Ethereum Experts Together To Explore Post-Pectra And Institutional Adoption
- Deribit And Signalplus Launch“The Summer Chase” Trading Competition 2025 Featuring A $300,000+ USDC Prize Pool
- G-Knot Appoints Fintech, Crypto Veteran Wes Kaplan As CEO To Launch The First Finger Vein Biometric Wallet
Comments
No comment